I am a
Home I AM A Search Login

Papers of the Week

Papers: 21 May 2022 - 27 May 2022

2022 May 23



Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study.


Basedau H, Sturm L-M, Mehnert J, Peng K-P, Schellong M, May A
Elife. 2022 May 23; 11.
PMID: 35604755.


Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alter central trigeminal pain processing; (ii) responders to galcanezumab treatment would show specific hypothalamic modulation in contrast to non-responders; and (iii) the ligand and the receptor antibody differ in brain responses.